FDA Approves First All-Oral Treatment for Adult Leukemia

The U.S. Food and Drug Administration has granted approval for a new combination therapy intended for adults with previously untreated chronic lymphocytic leukemia (CLL). This milestone establishes the first and only all-oral, fixed-duration regimen for these patients, allowing them to manage their condition without the need for traditional intravenous treatments.

Medical experts are calling the approval a significant win for patient flexibility. Because the treatment is a "fixed-duration" regimen, patients have the potential to take time off from medication once their initial treatment goals are met, rather than remaining on drugs indefinitely.

The approval was based on successful results from late-stage clinical trials that showed a meaningful improvement in long-term disease management. Pharmaceutical leaders say this move expands the options available to providers and patients who are navigating complex decisions regarding cancer care.

JPMorgan Report Shows U.S. Businesses Bearing Brunt of Tariffs

New research from the JP Morgan Chase Institute suggests that midsize American businesses are feeling the strain of recent tariff policies. The study found that tariff payments by these firms have tripled over the past year, directly contradicting claims that the financial burden falls primarily on foreign exporters. Businesses employing a total of 48 million people are reportedly facing mounting cost pressures as a result.

In response to these costs, many companies have been forced to raise prices for consumers or trim their hiring plans to protect profit margins. Some firms are also attempting to shift their supply chains away from China toward other regions in Asia to avoid the heaviest duties.

The White House has dismissed the findings, maintaining that the administration's trade strategy is necessary for long-term economic growth. However, recent figures from the U.S. Census Bureau show the trade deficit widening, adding further fuel to the debate over the effectiveness of the current tariff landscape.

Tech Giants Face Trial Over Social Media’s Impact on Youth

A landmark trial has begun in Los Angeles, centering on whether social media platforms like Meta and YouTube intentionally designed their products to be addictive to children. The case follows years of investigation into how these platforms handle child safety and mental health. A 20-year-old plaintiff, identified as KGM, is leading one of several "bellwether" cases that could set the tone for thousands of similar lawsuits nationwide.

Meta CEO Mark Zuckerberg testified this week, defending his company’s policies and emphasizing that the platform restricts users under the age of 13. However, attorneys for the families argue that the companies' algorithms are specifically crafted to keep young users engaged, often leading to issues like depression and eating disorders.

The outcome of this trial could fundamentally change how social media companies operate in the United States. If the jury finds the tech giants responsible for specific mental health harms, it could open the door for massive settlements and new federal regulations aimed at protecting minors online.